Table 4. Subgroup analysis of the association between RASSF1A promoter methylation and ovarian cancer.
| Cancer | Normal | M-H pooled OR† | D+L pooled OR‡ | Heterogeneity | |||||
| Group | M+ | N | M+ | N | OR (95% CI) | OR (95% CI) | I2 (%) | P | τ2 |
| Total | 364 | 763 | 32 | 438 | 11.17 (7.51–16.61) | 9.26 (5.30–16.19) | 29.0 | 0.153 | 0.27 |
| Population subgroup | |||||||||
| Asians | 249 | 510 | 22 | 314 | 13.97 (8.54–22.85) | 14.76 (5.73–38.01) | 55.0 | 0.038 | 0.74 |
| Caucasians | 115 | 253 | 10 | 124 | 6.85 (3.46–13.58) | 5.97 (2.96–12.05) | 0.0 | 0.724 | <0.01 |
| Case sample size | |||||||||
| <50 | 90 | 216 | 8 | 142 | 8.93 (4.33–18.42) | 6.96 (3.27–14.81) | 0 | 0.473 | <0.01 |
| ≥50 | 243 | 547 | 24 | 296 | 12.26 (7.62–19.72) | 11.19 (4.83–25.96) | 51.3 | 0.055 | 0.57 |
| Control type | |||||||||
| BAT | 356 | 743 | 29 | 336 | 8.95 (5.91–13.55) | 8.43 (4.03–17.63) | 48.3 | 0.031 | 0.67 |
| NT | 164 | 331 | 3 | 102 | 16.50 (6.82–39.88) | 12.82 (5.08–32.37) | 0.0 | 0.566 | <0.01 |
BAT: benign ovarian tissues and adjacent tissues; NT: normal ovarian tissues of cancer-free patients or healthy people.
†
the fixed-effects model.
‡
the random-effects model.